Favipiravir Sales Skyrocket in India Targeting Mild COVID-19 Cases
Doctors are prescribing ever more numbers of favipiravir-based drugs for patients with mild COVID-19
as it actually becomes India’s top selling drug in September with locally produced products that generated just under $20 million (US).
Domestic brands
are selling fast since their launch in June and, of course, as COVID-19 infections spread.The data
was derived from IMS IQVIA and the All Indian Origin Chemists & Distributors (AIOCD).Favipiravir Boom in India：
TrialSite reported on a number of different generic pharma company initiatives to develop and private label favipiravir products.
The Economic Times in India now reports 10 favipiravir-based brands in India, led in sales by Glenmark’s FabiFlu followed by Ciplan and Lupin.
Intense competition of course has led price declines in bids for position and market share. Prices have been cut to Rs 30 per tablet or about 41 cents per tablet.
https://www.trialsitenews.com/favipiravir-sales-skyrocket-in-india-targeting-mild-covid-19-cases/